Eli Lilly pomaglumetad methionil fails to meet primary endpoint in HBBM study

Eli Lilly and Company has reported negative results from H8Y-MC-HBBM (HBBM) study of pomaglumetad methionil, also known as mGlu2/3, conducted in patients suffering from an acute exacerbation of schizo…
Read the full story: PBR - Clinical Trials News